{"filing":{"accession_number":"0001628280-26-054330","cik":"0001806952","ticker":"LYEL","company_name":"Lyell Immunopharma, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"lyel-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1806952/000162828026054330/lyel-20260806.htm"},"events":[{"id":25906,"run_id":23521,"accession_number":"0001628280-26-054330","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release (Exhibit 99.1) discloses financial results including net loss of $44.8 million, operating expenses, cash position of $228.0 million, and cash runway guidance into Q3 2027. The filing explicitly states \"Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2026.\" This is material to investors as it provides quarterly financial performance and liquidity information.","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26842,"accession_number":"0001628280-26-054330","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release (Exhibit 99.1) discloses financial results including net loss of $44.8 million, operating expenses, cash position of $228.0 million, and cash runway guidance into Q3 2027. The filing explicitly states \"Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2026.\" This is material to investors as it provides quarterly financial performance and liquidity information.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:45:38.794031+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26842,"accession_number":"0001628280-26-054330","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) issued on August 6, 2026. The press release (Exhibit 99.1) discloses financial results including net loss of $44.8 million, operating expenses, cash position of $228.0 million, and cash runway guidance into Q3 2027. The filing explicitly states \"Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today reported financial results and business highlights for the second quarter ended June 30, 2026.\" This is material to investors as it provides quarterly financial performance and liquidity information.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:45:38.794031+00:00","company_name":"Lyell Immunopharma, Inc.","ticker":"LYEL","filing_date":"2026-08-06"}]}